Cobicistat (Tybost) for the treatment of HIV-1 infection in teenagers


Cobicistat (trade name: Tybost) been approved in Germany since September 2013 for the treatment of HIV-1 in adults. As of March 2020 it is also an option for the treatment of HIV-1 in teenagers aged 12 and over.

The human immunodeficiency (HIV) multiplies in cells of the and destroys them. Without proper treatment, the immune system of most HIV patients is weakened so much over time that they become seriously ill. This stage is called “AIDS” (acquired immunodeficiency syndrome).

Although the currently available medications can't cure HIV, they can prevent immunodeficiency for many years. But in some people the medication may become ineffective over time, allowing the viruses to multiply more again.

Cobicistat is a booster: It is combined with atazanavir or darunavir in order to enhance their effect.


Cobicistat is taken once a day in tablet form with a meal. Each tablets contains 150 mg cobicistat.

Other treatments

Teenagers with HIV infections who have treatment with atazanavir or darunavir are typically given ritonavir as a booster.


In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into into the advantages and disadvantages of cobicistat when used as a booster of atazanavir or darunavir in the treatment of HIV-1 infections in teenagers compared to the standard treatments.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The IQWiG review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of cobicistat (Tybost).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cobicistat (HIV infection in teenagers) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A20-37. June 29, 2020. (IQWiG reports; Volume 935).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on July 30, 2020
Next planned update: 2023


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.